重新设计Berberines和Sanguinarines以准可溶性环氧化酶,以提高抗炎功效

相关实验视频

Updated: Jun 5, 2025

06:21

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Xing-Zhou Liu¹, Xiao-Yu Du², Wei-Song Xie¹

¹Key Laboratory of Medicinal Molecule Science and Pharmaceutical Engineering, School of Chemistry and Chemical Engineering, Beijing Institute of Technology, Beijing 102488, China.

Journal of medicinal chemistry

|December 10, 2024

概括

新的氨基柏柏林衍生物被合成为强大的可溶性环氧化酶 (sEH) 抑制剂. 化合物LXZ-42在体内显著有效治疗炎症,具有出色的生物可用性和安全性.

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
有机合成有机合成

背景情况:

溶性环氧化酶 (sEH) 是一种被验证的炎症治疗点.
由于合成挑战,用于抑制sEH的天然产品支架仍未得到充分探索.
氨基柏衍生物提供了一个有希望的,但尚未探索的化学空间.

研究的目的:

开发可溶性环氧化酶 (sEH) 的新型,强效和有效抑制剂.
探索重新设计的天然产品对炎症的治疗潜力.
为了确定氨基柏林衍生物作为sEH抑制剂的结构-活性关系.

主要方法:

改性柏柏林和血类同类物与尿素功能的总合成.
结构-活性关系 (SAR) 研究以确定强效抑制剂.
在急性胰腺炎模型中的体内疗效测试,药物动力学分析和毒性评估.
对与sEH结合的化合物的晶体分析.

主要成果:

基拉尔四二二衍生物LXZ-42被确定为最强大的sEH抑制剂 (IC50 = 1.20nM).
在急性胰腺炎模型中,LXZ-42显示出显著的治疗效果,CYP酶相互作用最小.
对LXZ-42观察到优良的药理动力学特征,包括口服生物利用率为89.3%,没有急性体内毒性.
结晶学揭示了LXZ-42在sEH活性部位内的关键结合相互作用.

结论:

重新设计的氨基-柏柏林支架,特别是LXZ-42,代表了一种新型的强效sEH抑制剂.
LXZ-42在与炎症相关的疾病中表现出有前途的治疗潜力,得到了强大的体内疗效和有利的类似药物的特性的支持.
该研究强调了天然产品修饰在开发新的抗炎药物的价值.

相关概念视频

01:29

Drugs for Treatment of Ulcerative Colitis in IBD

119

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

119

02:57

Sharpless Epoxidation

3.8K

The conversion of allylic alcohols into epoxides using the chiral catalyst was discovered by K. Barry Sharpless and is known as Sharpless epoxidation. The use of a chiral catalyst enables the formation of one enantiomer of the product in excess. This chiral catalyst is mainly a chiral complex of titanium tetraisopropoxide and tartrate ester (specific stereoisomer). The stereoisomer used in the chiral catalyst dictates the formation of the enantiomer of the product. In other words, the use of...

3.8K

01:28

Structure-Activity Relationships and Drug Design

554

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

554

01:27

Combined Effects of Drugs: Synergism

3.7K

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...